C Elkins Ronald's insider trading at CryoLife
SEC Form 4 filings for RONALD C ELKINS,

Insider trading of C Elkins Ronald, a Director at CRY CryoLife, Inc.

Most recently C Elkins Ronald sold 1,000 shares worth $20,000.00 on 15 December 2017.

Date
#
Company
Insider Title
Trans.
Transaction
Shares Price per share Total price Shares after Source
2017-12-15 C Elkins Ronald
Director
Director Sale 1,000 $20.00 $20,000.00
2017-12-15
99,849 SEC insider form 4
2017-11-06 C Elkins Ronald
Director
Director Sale 1,000 $19.03 $19,030.00
2017-11-06
100,849 SEC insider form 4
2017-09-05 C Elkins Ronald
Director
Director Sale 1,000 $22.00 $22,000.00
2017-09-05
101,849 SEC insider form 4
2016-07-26 C Elkins Ronald
Director
Director Sale 2,000 $14.00 $28,000.00
2016-07-26
103,586 SEC insider form 4
2016-04-15 C Elkins Ronald
Director
Director Sale 1,000 $12.00 $12,000.00
2016-04-15
96,852 SEC insider form 4
2016-03-07 C Elkins Ronald
Director
Director Sale 2,000 $11.18 $22,360.00
2016-03-07
97,852 SEC insider form 4

CryoLife, Inc., together with its subsidiaries, manufactures and distributes medical devices worldwide. It also processes and distributes implantable human tissues for use in cardiac and vascular surgeries. The company operates in two segments, Medical Devices and Preservation Services. It offers surgical sealants and hemostats, including BioGlue Surgical Adhesive, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; BioFoam Surgical Matrix, which is used as an adjunct in sealing abdominal parenchymal tissues, as well as an adjunct for hemostasis in cardiovascular surgery; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries. The company also provides cardiac laser therapy products, which include laser console system and single-use, as well as fiber-optic hand-pieces for the treatment of coronary artery disease in patients with severe angina; and On-X heart valves for aortic and mitral indications. In addition, it distributes ProCol vascular bioprosthesis, a biological graft that provides vascular access for end-stage renal disease in hemodialysis patients; and PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities. Further, it distributes CryoValve SG pulmonary heart valves and CryoPatch SG pulmonary cardiac patch tissues that are processed using its proprietary SynerGraft technology; and vascular preservation services, such as CryoVein and CryoArtery tissues to treat various vascular reconstructions, such as peripheral bypass, hemodialysis access, and aortic infections. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.

  • CryoLife, Inc., 1655 Roberts Boulevard NW, Kennesaw 30144, United States
  • cryolife.com
  • 770-419-3355